PTI 555

Drug Profile

PTI 555

Alternative Names: morphine-naltrexone; MorViva

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Albert Einstein College of Medicine; Pain Therapeutics
  • Class Analgesics
  • Mechanism of Action Opioid mu receptor agonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 04 Oct 2002 Pain Therapeutics has completed a phase II trial in patients with postoperative pain
  • 13 May 2002 Pain Therapeutics has completed patient enrolment into a second phase II clinical trial in 160 patients with postoperative pain
  • 26 Mar 2002 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top